Latest Headlines

  1. UArizona Cancer Center Researchers Discover Iron-Targeting Approaches To Halt Proliferation Of Cancer Cells 9/11/2023

    Researchers at the University of Arizona Cancer Center discovered a new class of iron-targeting compounds that hamper the proliferation of cultured malignant cells in a laboratory setting. The results of the study were published in the Journal of the American Chemical Society.

  2. Verge Genomics Announces Artificial Intelligence-Enabled Drug Discovery Collaboration With Alexion For Rare Neurodegenerative And Neuromuscular Diseases 9/8/2023

    Verge Genomics, a clinical-stage biotechnology company transforming drug discovery using artificial intelligence (AI) and patient tissue data, today announced a multi-target collaboration with Alexion, AstraZeneca Rare Disease ("Alexion") to identify novel drug targets for rare neurodegenerative and neuromuscular diseases.

  3. Navigate BioPharma Services, Inc. Announces Collaboration With BD (Becton, Dickinson And Company) To Advance Capabilities For Clinical Phases Of Drug Development 9/7/2023

    Navigate BioPharma Services, Inc., a specialty laboratory offering high-quality, innovative precision medicine solutions and bioanalytics for clinical development and diagnostic applications, announces a strategic collaboration with BD (Becton, Dickinson and Company) (NYSE:BDX), a leading global medical technology company, to explore opportunities to develop and commercialize flow cytometry-based companion diagnostics and tools for clinical decisions.

  4. Amneal Receives U.S. FDA Approval For Lisdexamfetamine Dimesylate 9/6/2023

    Amneal Pharmaceuticals, Inc. (“Amneal” or the “Company”) today announced it has received Abbreviated New Drug Application (ANDA) approval from the U.S. Food and Drug Administration (“FDA”) for lisdexamfetamine dimesylate capsules, 20 mg, 30 mg, 40 mg, 50 mg, 60 mg, and 70 mg.

  5. Krystal Biotech Announces Orphan Drug Designation Granted To KB408 For The Treatment Of Alpha-1 Antitrypsin Deficiency 9/5/2023

    Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS), a commercial-stage biotechnology company focused on the discovery, development and commercialization of genetic medicines to treat diseases with high unmet medical needs, announced today that the U.S. Food and Drug Administration (FDA) granted Orphan Drug Designation for KB408 for the treatment of alpha-1 antitrypsin deficiency (AATD).

  6. X4 Pharmaceuticals Announces Submission Of New Drug Application (NDA) To U.S. FDA For Mavorixafor In WHIM Syndrome 9/5/2023

    X4 Pharmaceuticals (Nasdaq: XFOR), a company driven to improve the lives of people with rare diseases of the immune system, today announced the submission of a New Drug Application (NDA) to the United States Food and Drug Administration (FDA) for the approval of once-daily, oral mavorixafor to treat individuals aged 12 and older with WHIM (Warts, Hypogammaglobulinemia, Infections, and Myelokathexis) syndrome, a rare, primary immunodeficiency.

     

  7. uniQure Announces FDA Clearance Of Investigational New Drug Application For AMT-260 Gene Therapy For Refractory Mesial Temporal Lobe Epilepsy 9/5/2023

    uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today announced that the U.S. Food and Drug Administration (FDA) has cleared the Investigational New Drug (IND) application for AMT-260, the Company’s gene therapy candidate for refractory mesial temporal lobe epilepsy (MTLE).

  8. Pharmascience Canada Launches A New Generic Drug To Treat Hypertension 9/5/2023

    pms-PERINDOPRIL-INDAPAMIDE (perindopril erbumine / indapamide) is used in adults for the initial treatment of mild to moderate essential hypertension (high blood pressure).

  9. Intelligent OMICS Ltd In AI Driven Research Collaboration With Janssen 9/1/2023

    Intelligent OMICS Ltd (Intellomx), a leading biotechnology company that applies artificial intelligence (AI) to accelerate drug discovery, today announced a target discovery collaboration with Janssen Research & Development, LLC (Janssen), one of the Janssen Pharmaceutical Companies of Johnson & Johnson, to evaluate novel biological targets for the treatment of haematological cancers.

  10. Twist Bioscience Enters Into Agreement With Ono Pharmaceutical To Discover Novel Antibodies For Autoimmune Diseases 8/31/2023

    Twist Bioscience Corporation a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today announced a drug discovery agreement with Ono Pharmaceutical Co., Ltd. (Osaka, Japan; President and CEO: Gyo Sagara; “Ono”) to discover and develop novel antibodies for the treatment of autoimmune diseases.